Physician profile
John E Thompson
NPI 1447299771
$12,567.82
in general payments reported to CMS, 2019-2025
35 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $917 · 2021: $1,071 · 2022: $1,207 · 2023: $1,695 · 2024: $5,351 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,845 · Consulting Fee: $3,705 · Travel and Lodging: $63.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.58 |
| Consulting Fee | $3,705.00 |
| Travel and Lodging | $63.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,974.34 | 2024 | Susvimo |
| Johnson & Johnson Surgical Vision, INC. | $1,081.11 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Alcon Vision LLC | $1,062.96 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Mallinckrodt Hospital Products INC. | $810.48 | 2021-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $635.53 | 2019-2025 | |
| Abbvie INC. | $575.10 | 2022-2025 | Durysta, Vuity, Lumigan |
| Kala Pharmaceuticals, INC. | $525.12 | 2019-2022 | |
| New World Medical,INC. | $444.86 | 2023-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Novartis Pharmaceuticals Corporation | $395.97 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $377.62 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $316.60 | 2020-2023 | Tepezza |
| Glaukos Corporation | $289.39 | 2020-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $218.32 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Allergan, INC. | $200.44 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $195.39 | 2022-2024 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $193.91 | 2020 | |
| Biotissue Holdings INC. | $185.77 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $163.78 | 2021-2023 | Quatera 700 |
| Ocular Therapeutix, INC. | $130.13 | 2019-2023 | Dextenza |
| Amgen INC. | $121.67 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $118.02 | 2023-2025 | Vevye, Iheezo |
| Aerie Pharmaceuticals, INC. | $113.14 | 2019-2021 | |
| Dompe US, INC. | $65.91 | 2022-2025 | Oxervate |
| Omeros Corporation | $57.75 | 2019-2021 | |
| Oyster Point Pharma, INC. | $48.32 | 2022-2024 | Tyrvaya |
| Shire North American Group INC | $46.03 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.71 | 2019-2020 | |
| Rxsight INC | $35.03 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Ani Pharmaceuticals, INC. | $26.40 | 2024 | Purified Cortrophin Gel |
| Akorn, INC. | $24.02 | 2020 | |
| Genentech, INC. | $21.80 | 2019 | |
| Lensar, INC. | $19.81 | 2025 | Lensar Laser System |
| Thea Pharma INC. | $18.99 | 2023 | Iyuzeh |
| Astellas Pharma US INC | $18.15 | 2024 | Izervay |
| Carl Zeiss Meditec, INC. | $17.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.